This could be due to existing medical reasons or a history of illness with your family
The science is evolving rapidly, with multiple high-quality studies published in leading peer-reviewed journals consistently suggesting that GLP-1 therapy may offer meaningful protective effects against a range of obesity-related malignancies through mechanisms that operate both dependently and independently of weight loss
Why Nutrition Matters More Than Ever on a GLP-1 One of the most common challenges people experience on GLP-1 medications is simply not eating enough
If you have GLP-1 insurance coverage, your prescriber can help you choose which option might be most affordable
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
doi: 10.1016/0735-1097(95)00327-4 170 LandmesserUHornigBDrexlerH